Project Grant K08AI201821
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $191K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $853,847 to Massachusetts General Hospital on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds characterization of virologic and immunologic features of RSV immunoprophylaxis and escape. The recipient will sequence the genomes of approximately 3,000 biobanked and prospectively collected respiratory syncytial virus...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $220,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a dual germline-targeting immunization strategy eliciting broadly neutralizing antibodies against HIV-1. The research uses preclinical transgenic mouse models and data from an ongoing Phase 1 clinical trial (HVTN301) to optimize a prime-boost vaccination approach with the germline-targeting...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $278,333 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to assess the longitudinal impact of VRC01 prophylaxis on viral populations and autologous antibody responses in breakthrough infections. The research leverages longitudinal data from the Antibody Mediated Protection (AMP) Trial HVTN 704 and the follow-up Analytic Treatment Interruption (ATI) Trial...
- The National Institute of Allergy and Infectious Diseases awarded University of Wisconsin - Madison $449,375 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the structural mechanisms of respiratory syncytial virus and human metapneumovirus assembly. The project applies cryo-electron tomography, cryo-correlative light and electron microscopy, and cryo-focused ion beam milling, complemented by molecular biology and biochemical approaches, to...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $323,892 on April 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year research training program in mathematical modeling of SARS-CoV-2 variant emergence from immunocompromised hosts. The award funds development of a suite of mathematical models to understand mechanisms facilitating generation of SARS-CoV-2 variants of concern during prolonged...
- The National Institute of Allergy and Infectious Diseases awarded University of Kansas Medical Center Research Institute, Inc. $193,750 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct exploratory research on the role of cell-surface glycoRNAs in respiratory syncytial virus infection. The research will define the sequences and secondary structures of glycoRNAs that scaffold nucleolin, an RNA-binding protein and critical RSV entry receptor, on...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $238,899 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct preclinical evaluation of human monoclonal antibodies for herpes simplex virus type 2 (HSV-2) therapeutics. The research isolates and characterizes antibody-secreting cells discovered in genital skin tissue up to four months following HSV lesion healing. The project involves comprehensive...
- The National Institute of Allergy and Infectious Diseases awarded Washington State University $618,650 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on ZBP1 signaling in respiratory syncytial virus (RSV) triggered host defense and pathogenesis. The research examines how RSV activates the immune sensor protein ZBP1, which triggers necroptosis in infected stromal cells and pyroptosis in myeloid cells. The project investigates...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $879,998 on July 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of mucosal regulatory T cells in modulating tissue-resident memory T cell responses to infection. The research defines the features, fate, mechanisms, and functional consequences of regulatory T cells (Treg) and tissue Treg in anti-viral tissue memory immune responses in mice and...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $465,116 on April 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate AAV-delivered meganucleases as a therapeutic approach for durable control of genital herpes simplex virus infection. The R21 phase funds research extending prior work targeting HSV-1 to HSV-2, and determining whether intravenous or intrathecal administration is the optimal...